Además: mejora el cumplimiento terapéutico de la paciente y presenta menor incidencia de efectos adversos. Un dato terapéutico importante para las pacientes con alopecia androgenética.
Fuente: revista de la academia americana de Dermatología (JAAD-diciembre 2011)
J Am Acad Dermatol. 2011 Jun 21. [Epub ahead of print]
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.
Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Germany.
We sought to compare the efficacy, safety, and acceptability and to show noninferiority of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% MTS in women with androgenetic alopecia.
A total of 113 women with androgenetic alopecia were randomized to 24 weeks of treatment with 5% MTF or 2% MTS. The primary efficacy parameter was change from baseline in nonvellus target area hair count at week 24. Secondary end points included change in nonvellus target area hair width, overall efficacy by global photographic review as assessed by treatment-blinded evaluators and the subject herself, adverse events, and participants' assessment of product aesthetics.
After 24 weeks, women randomized to 5% MTF once daily showed noninferior target area hair count and target area hair width and experienced greater, but nonsignificant, improvements in target area hair count, target area hair width, and overall efficacy by global photographic review than those randomized to 2% MTS used twice daily. 5% MTF was significantly superior to 2% MTS in participants' agreement with "the treatment does not interfere with styling my hair" (P = .002). Women randomized to 5% MTF experienced significantly lower rates of local intolerance (P = .046) especially in pruritus and dandruff compared with 2% MTS.
Because of differences in the formulations tested, study participants were not blinded to treatment.
Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia and is associated with several aesthetic and practical advantages.
Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
[PubMed - as supplied by publisher]
Dr. Sergio Vañó Galván
Dermatólogo del Hospital Universitario Ramón y Cajal en Madrid y de la Clínica Grupo de Dermatología Pedro Jaén. Coordinador de la Unidad de Tricología y estudio de las alopecias del Hospital Ramón y Cajal y de la Clínica Grupo de Dermatología Jaén.Doctor en Medicina. Profesor Honorífico de la Universidad de Alcalá.
Página web: http://www.sergiovano.com/Twitter: @sergiovanog